Edition:
United States

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

23.61USD
20 Apr 2018
Change (% chg)

$0.05 (+0.21%)
Prev Close
$23.56
Open
$23.49
Day's High
$24.01
Day's Low
$23.41
Volume
88,919
Avg. Vol
122,828
52-wk High
$32.57
52-wk Low
$14.36

Chart for

About

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology... (more)

Overall

Beta: 2.46
Market Cap(Mil.): $976.49
Shares Outstanding(Mil.): 41.36
Dividend: --
Yield (%): --

Financials

  MGNX.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -0.62 -- --
ROI: -6.45 -0.74 13.19
ROE: -6.91 -2.80 15.00

BRIEF-Macrogenics Inc Prices Of Public Offering

* MACROGENICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Mar 28 2018

BRIEF-Macrogenics Announces Proposed Public Offering Of Common Stock

* MACROGENICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 26 2018

BRIEF-Macrogenics Provides Update On Corporate Progress And 2017 Financial Results

* MACROGENICS PROVIDES UPDATE ON CORPORATE PROGRESS AND 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Macrogenics Enters Research Collaboration With Roche

* MACROGENICS ENTERS RESEARCH COLLABORATION WITH ROCHE TO DEVELOP A NOVEL BISPECIFIC MOLECULE

Jan 04 2018

BRIEF-Macrogenics- increased number of directors that constitute board from eight to nine ​

* Macrogenics- increased number of directors that constitute board from eight to nine after approving appointment of Jay Siegel on Nov 13 - SEC filing ​ Source text: (http://bit.ly/2A2CHjE) Further company coverage:

Nov 16 2017

BRIEF-Macrogenics names Jay Siegel to its board of directors

* Macrogenics names Jay Siegel to its board of directors Source text for Eikon: Further company coverage:

Nov 15 2017

BRIEF-Macrogenics Posts Q3 loss of $1.28 per share

* Macrogenics provides update on corporate progress and third quarter 2017 financial results

Nov 08 2017

BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement

* Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012

Oct 25 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF215.65 -0.85
Roche Holding Ltd. (RO.S) CHF220.00 -0.20
Amgen, Inc. (AMGN.OQ) $171.56 -1.37
Xencor Inc (XNCR.OQ) $29.88 +0.18

Earnings vs. Estimates